Medications for Opioid Use Disorder and Mortality and Hospitalization Among People With Opioid Use-related Infections.
Journal
Epidemiology (Cambridge, Mass.)
ISSN: 1531-5487
Titre abrégé: Epidemiology
Pays: United States
ID NLM: 9009644
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
medline:
1
12
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
ppublish
Résumé
Severe skin and soft tissue infections related to injection drug use have increased in concordance with a shift to heroin and illicitly manufactured fentanyl. Opioid agonist therapy medications (methadone and buprenorphine) may improve long-term outcomes by reducing injection drug use. We aimed to examine the association of medication use with mortality among people with opioid use-related skin or soft tissue infections. An observational cohort study of Medicaid enrollees aged 18 years or older following their first documented medical encounters for opioid use-related skin or soft tissue infections during 2007-2018 in North Carolina. The exposure was documented medication use (methadone or buprenorphine claim) in the first 30 days following initial infection compared with no medication claim. Using Kaplan-Meier estimators, we examined the difference in 3-year incidence of mortality by medication use, weighted for year, age, comorbidities, and length of hospital stay. In this sample, there were 13,286 people with opioid use-related skin or soft tissue infections. The median age was 37 years, 68% were women, and 78% were white. In Kaplan-Meier curves for the total study population, 12 of every 100 patients died during the first 3 years. In weighted models, for every 100 people who used medications, there were four fewer deaths over 3 years (95% confidence interval = 2, 6). In this study, people with opioid use-related skin and soft tissue infections had a high risk of mortality following their initial healthcare visit for infections. Methadone or buprenorphine use was associated with reductions in mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Severe skin and soft tissue infections related to injection drug use have increased in concordance with a shift to heroin and illicitly manufactured fentanyl. Opioid agonist therapy medications (methadone and buprenorphine) may improve long-term outcomes by reducing injection drug use. We aimed to examine the association of medication use with mortality among people with opioid use-related skin or soft tissue infections.
METHODS
METHODS
An observational cohort study of Medicaid enrollees aged 18 years or older following their first documented medical encounters for opioid use-related skin or soft tissue infections during 2007-2018 in North Carolina. The exposure was documented medication use (methadone or buprenorphine claim) in the first 30 days following initial infection compared with no medication claim. Using Kaplan-Meier estimators, we examined the difference in 3-year incidence of mortality by medication use, weighted for year, age, comorbidities, and length of hospital stay.
RESULTS
RESULTS
In this sample, there were 13,286 people with opioid use-related skin or soft tissue infections. The median age was 37 years, 68% were women, and 78% were white. In Kaplan-Meier curves for the total study population, 12 of every 100 patients died during the first 3 years. In weighted models, for every 100 people who used medications, there were four fewer deaths over 3 years (95% confidence interval = 2, 6).
CONCLUSION
CONCLUSIONS
In this study, people with opioid use-related skin and soft tissue infections had a high risk of mortality following their initial healthcare visit for infections. Methadone or buprenorphine use was associated with reductions in mortality.
Identifiants
pubmed: 37820243
doi: 10.1097/EDE.0000000000001681
pii: 00001648-990000000-00192
doi:
Substances chimiques
Analgesics, Opioid
0
Methadone
UC6VBE7V1Z
Buprenorphine
40D3SCR4GZ
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7-15Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
McCarthy NL, Baggs J, See I, et al. Bacterial infections associated with substance use disorders, large cohort of united states hospitals, 2012–2017. Clin Infect Dis. 2020;71:e37–e44.
Kadri Amer N, Wilner B, Hernandez AV, et al. Geographic trends, patient characteristics, and outcomes of infective endocarditis associated with drug abuse in the United States from 2002 to 2016. J Am Heart Assoc. 2019;8:e012969.
Schranz AJ, Fleischauer A, Chu VH, Wu LT, Rosen DL. Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017: a study of statewide discharge data. Ann Intern Med. 2019;170:31–40.
Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39–49.
Phillips KT, Anderson BJ, Herman DS, Liebschutz JM, Stein MD. Risk factors associated with skin and soft tissue infections among hospitalized people who inject drugs. J Addict Med. 2017;11:461–467.
Figgatt MC, Salazar ZR, Vincent L, et al. Treatment experiences for skin and soft tissue infections among participants of syringe service programs in North Carolina. Harm Reduct J. 2021;18:80.
Sredl M, Fleischauer AT, Moore Z, Rosen DL, Schranz AJ. Not just endocarditis: hospitalizations for selected invasive infections among persons with opioid and stimulant use diagnoses—North Carolina, 2010–2018. J Infect Dis. 2020;222:S458–S464.
Kerr T, Wood E, Grafstein E, et al. High rates of primary care and emergency department use among injection drug users in Vancouver. J Public Health (Oxf). 2005;27:62–66.
Centers for Disease Control and Prevention (CDC). Soft tissue infections among injection drug users--San Francisco, California, 1996-2000. MMWR Morb Mortal Wkly Rep. 2001;50:381–384.
See I, Gokhale RH, Geller A, et al. National public health burden estimates of endocarditis and skin and soft-tissue infections related to injection drug use: a review. J Infect Dis. 2020;222:S429–S436.
Leahey PA, LaSalvia MT, Rosenthal ES, Karchmer AW, Rowley CF. High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis. Open Forum Infect Dis. 2019;6:ofz089.
Goodman-Meza D, Weiss RE, Gamboa S, et al. Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis. BMC Infect Dis. 2019;19:918.
Santo T, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78:979–993.
Dong H, Hayashi K, Milloy MJ, et al. Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Drug Alcohol Depend. 2020;212:108005.
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–920.
Medicaid Enrollee Supplemental File (MESF): National Death Index (NDI) Segment. ResDAC. Available at: https://resdac.org/cms-data/files/mesf-ndi . Accessed 28 March 2023.
Race and Ethnicity Constructed Code - Latest in Year. ResDAC. Available at: https://resdac.org/cms-data/variables/race-and-ethnicity-constructed-code-latest-year . Accessed 28 March 2023.
Sun JW, Rogers JR, Her Q, et al. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55:1046–1051.
Hajage D, Tubach F, Steg PG, Bhatt DL, De Rycke Y. On the use of propensity scores in case of rare exposure. BMC Med Res Methodol. 2016;16:38.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424.
Brothers TD, Lewer D, Jones N, et al. Opioid agonist treatment and risk of death or rehospitalization following injection drug use-associated bacterial and fungal infections: a cohort study in New South Wales, Australia. PLoS Med. 2022;19:e1004049.
Marks LR, Munigala S, Warren DK, et al. A comparison of medication for opioid use disorder treatment strategies for persons who inject drugs with invasive bacterial and fungal infections. J Infect Dis. 2020;222:S513–S520.
Barocas JA, Gai MJ, Amuchi B, Jawa R, Linas BP. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020;215:108207.
Palepu A, Tyndall MW, Leon H, et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 2001;165:415–420.
Serota DP, Tookes HE, Hervera B, et al. Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team. Ann Med. 2021;53:1960–1968.
Ginoza MEC, Tomita-Barber J, Onugha J, et al. Student-Run free clinic at a syringe services program, miami, Florida, 2017–2019. Am J Public Health. 2020;110:988–990.
Jakubowski A, Norton BL, Hayes BT, et al. Low-threshold buprenorphine treatment in a syringe services program: program description and outcomes. J Addict Med. 2022;16:447–453.
Donohue JM, Jarlenski MP, Kim JY, et al.; Medicaid Outcomes Distributed Research Network (MODRN). Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 States, 2014-2018. JAMA. 2021;326:154–164.
McBain RK, Dick A, Sorbero M, Stein BD. Growth and distribution of buprenorphine-waivered providers in the United States, 2007–2017. Ann Intern Med. 2020;172:504–506.
Schiff DM, Nielsen T, Hoeppner BB, et al. Assessment of racial and ethnic disparities in the use of medication to treat opioid use disorder among pregnant women in Massachusetts. JAMA Netw Open. 2020;3:e205734.
Alinsky RH, Zima BT, Rodean J, et al. Receipt of addiction treatment after opioid overdose among Medicaid-enrolled adolescents and young adults. JAMA Pediatr. 2020;174:e195183.
Weinstein ZM, Kim HW, Cheng DM, et al. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65–70.
Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40:367–377.
Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35:22–35.
Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2:109–112.
Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–764.
Figgatt MC, Schranz AJ, Hincapie-Castillo JM, Golightly YM, Marshall SW, Dasgupta N. Complications in using real-world data to study the health of people who use drugs. Epidemiology. 2023;34:259–264.
Kariisa M, O'Donnell J, Kumar S, Mattson CL, Goldberger BA. Illicitly manufactured fentanyl–involved overdose deaths with detected xylazine — United States, January 2019–June 2022. MMWR Morb Mortal Wkly Rep. 2023;72:721–727.
Ruiz-Colón K, Chavez-Arias C, Díaz-Alcalá JE, Martínez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature. Forensic Sci Int. 2014;240:1–8.